SOURCES SOUGHT
A -- A Pooled Investigation of Circulating Adiponectin Levels and Risk of Multiple Myeloma - Statement of Work
- Notice Date
- 8/1/2013
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions-Treatment and Support Branch, Bldg 244, Room 112, Frederick, Maryland, 21702
- ZIP Code
- 21702
- Solicitation Number
- HHSN-NIH-NCI-SBSS-TSB-34404-11
- Archive Date
- 8/23/2013
- Point of Contact
- Brenda Oberholzer, Phone: 301-624-8750
- E-Mail Address
-
oberholzerb@mail.nih.gov
(oberholzerb@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Statement of Work A Pooled Investigation of Circulating Adiponectin Levels and Risk of Multiple Myeloma This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned a code of 541711 in the North American Industry Classification System (NAICS), and the size standard for such requirements is 500 employees. It has been hypothesized that the observed excess risk of multiple myeloma (MM) among obese individuals could be due to altered circulating levels of andiponectin, a polypeptide hormone with anti-inflammatory properties secreted by adipose tissue. In a recent prospective investigation of 174 MM cases and 348 controls in the Prostate, Lung, Colorectal, and Ovarian Screening Trial, we observed inverse associations with MM for both total and high-molecular-weight (HMW) adiponectin. The results of this study suggest that adiponectin may play a role in obesity-related myelomagenesis, although replication of these findings in other prospective cohorts is critical. Findings from other recent studies suggest that altered circulating levels of resistin, another hormone secreted by adipose tissue, may also influence MM risk. In an effort to replicate our PLCO findings for adiponectin and extend our investigation to resistin, we are conducting a pooled nested case-control study using prospectively collected blood samples from six cohorts participating in the NCI Cohort Consortium. The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), is anticipating to award a Firm-Fixed Price non-competitive purchase order to Jewish General Hospital in Montreal, Canada to provide analytes measurements that are scientifically comparable with prior findings. Contractor Requirements: The contractor shall measure levels of total and HMW adiponectin in 1,672 samples, and levels of resistin in 635 samples from the cohorts participating in this investigation. The Contractor shall perform the following tasks: 1. Receive the samples from each institution and log them in the laboratory tracking system; 2. Conduct requested assays measuring circulating levels of total adiponectin, HMW adiponectin, and resistin; 3. Record assay results, test date, and batching information; and 4. Provide these data to the NCI Contracting Officer's Representative (COR) no later than September 29, 2014. To be deemed capable of providing the current need the offeror must submit a written capability statement. Organizations that submit capability statements in response to this notice will be evaluated against the following technical areas of experience and expertise: 1. Personnel/Experience: a. Proven organizational and past experience in measuring circulating levels of total adiponectin, HMW adiponectin, and resistin in samples from selected subjects from multiple cohorts. b. The offeror shall provide the name of the Principal Investigator, his/her professional qualifications and specific experience as a key investigator in measuring analytes and possessing sufficient authority to assure access to facilities and records required for the project. c. The offeror shall demonstrate that the proposed team and staff have previous successful experience in carrying out the requirements of the services stated herein. 2. Facilities: Adequacy of facilities for performing the Statement of Work. If any responsible source believes it can perform the requirements they may submit their capability statements via email (PDF format; 15 Page Limit, these pages exclude resumes) for consideration by NCI to Brenda Oberholzer, Contracting Officer, at the e-mail address provided by the response date. No collect calls or facsimile transmissions will be accepted. Respondents must include DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HUBZONE, etc) pursuant to the applicable NAICS code. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation(s). Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF2/HHSN-NIH-NCI-SBSS-TSB-34404-11/listing.html)
- Record
- SN03134537-W 20130803/130801235809-04d651decc45b83e7d99cf7c53da3e16 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |